Precision BioSciences Joins Russell 2000, Boosting Institutional Visibility

Key Facts

In a move that lifts the profile of small-cap stocks, Precision BioSciences announced its inclusion in the Russell 2000 Index, effective June 26, 2026, according to FTSE Russell's final reconstitution list. The Nasdaq-listed gene-editing firm joins the benchmark of roughly 2,000 small-cap U.S. companies, expanding its visibility among institutional investors.

The addition follows the annual rebalancing of Russell U.S. indexes, which is based on market capitalization and eligibility criteria. Index inclusion typically triggers passive inflows as tracking funds adjust their portfolios. DTIL closed at $7.29 on Friday, hitting a high of $7.60 during the session, per market data for June 26, 2026.

Investors may watch trading volumes in the coming weeks to gauge the scale of institutional flows tied to the index addition. The gene-editing sector's clinical and regulatory milestones remain a longer-term catalyst. For now, with no near-term earnings or trial readouts on the calendar, the index inclusion itself serves as the primary sentiment driver for the stock.